Cargando…

Presepsin levels and COVID-19 severity: a systematic review and meta-analysis

Plasmatic presepsin (PSP) is a novel biomarker reported to be useful for sepsis diagnosis and prognosis. During the pandemic, only few studies highlighted a possible correlation between PSP and COVID-19 severity, but results remain inconsistent. The present study aims to establish the correlation be...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarino, Matteo, Perna, Benedetta, Maritati, Martina, Remelli, Francesca, Trevisan, Caterina, Spampinato, Michele Domenico, Costanzini, Anna, Volpato, Stefano, Contini, Carlo, De Giorgio, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666937/
https://www.ncbi.nlm.nih.gov/pubmed/36380007
http://dx.doi.org/10.1007/s10238-022-00936-8
_version_ 1784831613773807616
author Guarino, Matteo
Perna, Benedetta
Maritati, Martina
Remelli, Francesca
Trevisan, Caterina
Spampinato, Michele Domenico
Costanzini, Anna
Volpato, Stefano
Contini, Carlo
De Giorgio, Roberto
author_facet Guarino, Matteo
Perna, Benedetta
Maritati, Martina
Remelli, Francesca
Trevisan, Caterina
Spampinato, Michele Domenico
Costanzini, Anna
Volpato, Stefano
Contini, Carlo
De Giorgio, Roberto
author_sort Guarino, Matteo
collection PubMed
description Plasmatic presepsin (PSP) is a novel biomarker reported to be useful for sepsis diagnosis and prognosis. During the pandemic, only few studies highlighted a possible correlation between PSP and COVID-19 severity, but results remain inconsistent. The present study aims to establish the correlation between PSP and COVID-19 severity. English-language papers assessing a correlation between COVID-19 and PSP from MEDLINE, PubMed, Google Scholar, Cochrane Library, MeSH, LitCovid NLM, EMBASE, CINAHL Plus and the World Health Organization (WHO) website, published from January 2020 were considered with no publication date limitations. Two independent reviewers performed data abstraction and quality assessment, and one reviewer resolved inconsistencies. The protocol was registered on PROSPERO (CRD42022325971).Fifteen articles met our eligibility criteria. The aggregate study population included 1373 COVID-19 patients who had undergone a PSP assessment. The random-effect meta-analysis was performed in 7 out of 15 selected studies, considering only those reporting the mean PSP levels in low- and high-severity cases (n = 707).The results showed that the pooled mean difference of PSP levels between high- and low-severity COVID-19 patients was 441.70 pg/ml (95%CI: 150.40–732.99 pg/ml).Our data show that presepsin is a promising biomarker that can express COVID-19 severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-022-00936-8.
format Online
Article
Text
id pubmed-9666937
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96669372022-11-16 Presepsin levels and COVID-19 severity: a systematic review and meta-analysis Guarino, Matteo Perna, Benedetta Maritati, Martina Remelli, Francesca Trevisan, Caterina Spampinato, Michele Domenico Costanzini, Anna Volpato, Stefano Contini, Carlo De Giorgio, Roberto Clin Exp Med Review Article Plasmatic presepsin (PSP) is a novel biomarker reported to be useful for sepsis diagnosis and prognosis. During the pandemic, only few studies highlighted a possible correlation between PSP and COVID-19 severity, but results remain inconsistent. The present study aims to establish the correlation between PSP and COVID-19 severity. English-language papers assessing a correlation between COVID-19 and PSP from MEDLINE, PubMed, Google Scholar, Cochrane Library, MeSH, LitCovid NLM, EMBASE, CINAHL Plus and the World Health Organization (WHO) website, published from January 2020 were considered with no publication date limitations. Two independent reviewers performed data abstraction and quality assessment, and one reviewer resolved inconsistencies. The protocol was registered on PROSPERO (CRD42022325971).Fifteen articles met our eligibility criteria. The aggregate study population included 1373 COVID-19 patients who had undergone a PSP assessment. The random-effect meta-analysis was performed in 7 out of 15 selected studies, considering only those reporting the mean PSP levels in low- and high-severity cases (n = 707).The results showed that the pooled mean difference of PSP levels between high- and low-severity COVID-19 patients was 441.70 pg/ml (95%CI: 150.40–732.99 pg/ml).Our data show that presepsin is a promising biomarker that can express COVID-19 severity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-022-00936-8. Springer International Publishing 2022-11-15 2023 /pmc/articles/PMC9666937/ /pubmed/36380007 http://dx.doi.org/10.1007/s10238-022-00936-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Guarino, Matteo
Perna, Benedetta
Maritati, Martina
Remelli, Francesca
Trevisan, Caterina
Spampinato, Michele Domenico
Costanzini, Anna
Volpato, Stefano
Contini, Carlo
De Giorgio, Roberto
Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title_full Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title_fullStr Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title_full_unstemmed Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title_short Presepsin levels and COVID-19 severity: a systematic review and meta-analysis
title_sort presepsin levels and covid-19 severity: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666937/
https://www.ncbi.nlm.nih.gov/pubmed/36380007
http://dx.doi.org/10.1007/s10238-022-00936-8
work_keys_str_mv AT guarinomatteo presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT pernabenedetta presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT maritatimartina presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT remellifrancesca presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT trevisancaterina presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT spampinatomicheledomenico presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT costanzinianna presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT volpatostefano presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT continicarlo presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis
AT degiorgioroberto presepsinlevelsandcovid19severityasystematicreviewandmetaanalysis